These results showed that the IL-6 inhibitor (Tocilizumab) and CIGB-258 were superior in attenuating the acute inflammation of CML than the TNF-α inhibitors (Infliximab and Etanercept), resulting in faster recovery of the swimming ability and higher survivability (Figure 9). This evidence concerns the gene IL6 and chronic myelogenous leukemia, BCR-ABL1 positive.